


Immunotherapy Response and Resistance in Patients with Advanced Uveal Melanoma; a retrospective cohort study

Alexander Maurer^{1*}, Giulio Clerici^{2*}, Jan A. Schaab¹, Phil F. Cheng³, Daniela Mihic-Probst⁴, Cäcilia Mader¹, Michael Messerli¹, Martin W Huellner¹, Reinhard Dummer², Florentia Dimitriou²


1. Department of Nuclear Medicine, University Hospital of Zurich, University of Zurich, Zurich, Switzerland
2. Department of Dermatology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland
3. Department of Oncology, Geneva University Hospital, Geneva, Switzerland
4. Institute for Pathology and Molecular Pathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland

* Equal contribution as joint first authors


A Progression free survival




B Overall survival




Supplementary Figure 1. Kaplan-Meier curve for progression free survival (PFS) (A) and overall survival (OS) (B) of patients treated with the immune checkpoint inhibitors (ICI) ipilimumab/nivolumab.




Supplementary Figure 2. Kaplan-Meier curve for progression-free survival (PFS) by lactate dehydrogenase (LDH) level at treatment start with ipilimumab/nivolumab.




Supplementary Figure 3. Kaplan-Meier curve for overall survival (OS) by lactate dehydrogenase (LDH) level at treatment start with ipilimumab/nivolumab.



Supplementary Figure 4. Kaplan-Meier curve for progression-free survival (PFS) (A) and overall survival (OS) (B) of patients treated with tebentafusp.



Supplementary Figure 5. Kaplan-Meier curve for progression-free survival (PFS) by lactate dehydrogenase (LDH) level at treatment start with tebentafusp.



Supplementary Figure 6. Kaplan-Meier curve for overall survival (OS) by lactate dehydrogenase (LDH) level at treatment start with tebentafusp.